Kalevi Kurkijärvi
Vorstandsvorsitzender bei Fibrogen Europe Oy
Aktive Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
James Schoeneck | M | 66 | 14 Jahre | |
Thane Wettig | M | 59 | 4 Jahre | |
Jeffrey Edwards | M | 64 | 9 Jahre | |
Aoife Brennan | M | 48 | 4 Jahre | |
Suzanne Blaug | F | 66 | 5 Jahre | |
Jeffrey Henderson | M | 59 | 9 Jahre | |
Meichiel Keenan | F | - | 20 Jahre | |
Gerald Lema | M | 63 | 7 Jahre | |
Juha Aimo Koivurinta | M | - |
Fibrogen Europe Oy
Fibrogen Europe Oy BiotechnologyHealth Technology Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland. | 24 Jahre |
Benjamin Cravatt | M | 54 | 4 Jahre | |
May Kin Ho | M | 71 | 6 Jahre | |
Kirk A. Christoffersen | M | 56 | 4 Jahre | |
Leanne C. Price | F | - | 25 Jahre | |
Al Y. Lin | M | - | 25 Jahre | |
James Wallace Polarek | M | - |
Fibrogen Europe Oy
Fibrogen Europe Oy BiotechnologyHealth Technology Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland. | 27 Jahre |
Jorma Tapio Routti | M | 85 |
Fibrogen Europe Oy
Fibrogen Europe Oy BiotechnologyHealth Technology Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland. | 23 Jahre |
Günther Schumacher | M | - |
Fibrogen Europe Oy
Fibrogen Europe Oy BiotechnologyHealth Technology Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland. | 25 Jahre |
Elias Kouchakji | M | 67 | 10 Jahre | |
Christine Chung L. | F | 56 | 17 Jahre | |
Fred S. Apple | M | - |
Hytest Oy
Hytest Oy BiotechnologyHealth Technology Hytest Oy manufactures biological products. It operates as producer of monoclonal antibodies and antigens for the diagnostic industry. The company was founded in 1994 and is headquartered in Turku, Finland. | 8 Jahre |
Tricia Stewart | F | - | 3 Jahre | |
Michael D. Lowenstein | M | - | 21 Jahre |
Beziehungs-Chart
Beziehungen zu mehreren Unternehmen
Ehemalige Beziehungen
Name | Geschlecht | Alter | Unternehmensverbindungen | Zusammenarbeit |
---|---|---|---|---|
Thomas Byron Neff | M | 69 |
Fibrogen Europe Oy
Fibrogen Europe Oy BiotechnologyHealth Technology Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland. | 26 Jahre |
Beverly A. Armstrong | F | 55 |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | - |
Julian N. Stern | M | 99 | 25 Jahre | |
Thomas Kearns | M | 87 | 26 Jahre | |
Tony Sun | M | 52 |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | - |
Patrik Olof Dahlén | M | 62 |
University of Turku
Wallac Oy
| 6 Jahre |
Patricio Miguel Madero Blasquez | M | 74 | 20 Jahre | |
Enrique Conterno | M | 57 | 3 Jahre | |
Tanja Dowe | F | - |
Innomedica Oy
Innomedica Oy Miscellaneous Commercial ServicesCommercial Services Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small. | 16 Jahre |
Kathryn M. Boxmeyer | F | 49 |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | - |
Karen L. Bergman | F | - | - | |
Pat Cotroneo | M | 60 | 21 Jahre | |
Roberto Pedro Rosenkranz | M | 74 | 10 Jahre | |
Toshinari Tamura | M | 80 | 12 Jahre | |
John P. Dunphy | M | - |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | - |
Marko Matti Ensio Järvinen | M | 54 |
Fibrogen Europe Oy
Fibrogen Europe Oy BiotechnologyHealth Technology Fibrogen Europe Oy develops and markets recombinant human collagens and gelatins for research purposes. It serves companies in the pharmaceutical, vaccine, medical device, diagnostic, industrial, food, cosmetic, and nutraceutical businesses. The company was founded on May 22, 1996 and is located at Helsinki, Finland. | 5 Jahre |
Seth Porter | M | - | 13 Jahre | |
Percy Carter | M | 53 | 1 Jahre | |
Esa Ikäheimonen | M | 61 |
University of Turku
| 3 Jahre |
Christopher J. Molineaux | M | 70 | 4 Jahre | |
Paul White | M | - |
Hytest Oy
Hytest Oy BiotechnologyHealth Technology Hytest Oy manufactures biological products. It operates as producer of monoclonal antibodies and antigens for the diagnostic industry. The company was founded in 1994 and is headquartered in Turku, Finland. | - |
Greg Mann | M | - | - | |
Paul J. Frohna | M | - | 1 Jahre | |
Solveig Sjöblom | F | - |
Innomedica Oy
Innomedica Oy Miscellaneous Commercial ServicesCommercial Services Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small. | 8 Jahre |
Lassi Tapani Noponen | M | 61 |
University of Turku
| 7 Jahre |
Merja Elina Leino | M | 64 |
University of Turku
| 2 Jahre |
Nina Arkilahti | F | 57 |
University of Turku
| 1 Jahre |
Laura G. Hansen | M | - | 10 Jahre | |
Michael Martinelli | M | - | 11 Jahre | |
Brain Roberts | M | 49 | 5 Jahre | |
Gerd Kochendoerfer | M | 56 | 3 Jahre | |
Dennis Purcell | M | 68 |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | - |
Pasi Jänkälä | M | - |
Bio Fund Management Oy
Bio Fund Management Oy Investment ManagersFinance BioFund Management Oy is a venture capital and private equity investment firm headquartered in Helsinki with an office in Turku and a subsidiary in Copenhagen. BioFund was founded in 1997 by Dr. Kalevi Kurkijärvi, Seppo Mäkinen and Dr. Timo Petäjä. BioFund's main investors are institutions in Finland such as insurance firms, pension funds, foundations, and the European Investment Fund. The firm manages venture capital funds. | 8 Jahre |
Tero Piispanen | M | - |
Innomedica Oy
Innomedica Oy Miscellaneous Commercial ServicesCommercial Services Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small. | 7 Jahre |
Russell Ellison | M | 76 | 2 Jahre | |
Robert D. Arbeit | M | 76 |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | 6 Jahre |
Frank Valone | M | 74 | 8 Jahre | |
David Liu | M | 73 | 8 Jahre | |
Maarit Pelkonen | F | - |
University of Turku
| 4 Jahre |
Risto Arvo Sakari Lammintausta | M | - |
Innomedica Oy
Innomedica Oy Miscellaneous Commercial ServicesCommercial Services Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small. | - |
Hannu Sundqvist | M | - |
Innomedica Oy
Innomedica Oy Miscellaneous Commercial ServicesCommercial Services Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small. | - |
Tom Edelman | M | - |
Innomedica Oy
Innomedica Oy Miscellaneous Commercial ServicesCommercial Services Innomedica is an international business consulting company serving the biotechnology and pharmaceutical industries. It provides a range of professional business development and project management services to its clients in both the public and private sectors. Innomedica's service portfolio includes Business Development, Licensing & Partnering, Japan Markets and Project Management. It is active on a global basis, though it specializes in the North European and Japanese markets. Its people are its main asset. Its success is based on leveraging the experience of professionals from different disciplines to deliver value to its clients. Its team portrays backgrounds from experienced business people to skilled lawyers and biomedical scientists. Innomedica was founded in 1997, and is a privately held company. Its client base covers both private and public sectors, both large and small. | 12 Jahre |
Markku Tapani Jalkanen | M | 70 |
University of Turku
| - |
Kin Hung Yu | M | 61 | 12 Jahre | |
Alex Michine | M | - |
Hytest Oy
Hytest Oy BiotechnologyHealth Technology Hytest Oy manufactures biological products. It operates as producer of monoclonal antibodies and antigens for the diagnostic industry. The company was founded in 1994 and is headquartered in Turku, Finland. | - |
S. Ken Tanaka | M | 72 |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | - |
Sean M. Johnston | M | 66 |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | - |
Dennis Patrick Molnar | M | 55 |
Paratek Pharmaceuticals, Inc. /Old/
Paratek Pharmaceuticals, Inc. /Old/ Pharmaceuticals: MajorHealth Technology Paratek Pharmaceuticals, Inc. operates as a pharmaceutical company that focuses on the discovery, development, and commercialization of medicines. The firm’s lead product candidate, omadacycline, is a new tetracycline-derived, broad-spectrum antibiotic being developed for use as a first-line monotherapy for serious community-acquired bacterial infections where antibiotic resistance is of concern for treating physicians. The company was founded by Stuart B. Levy and Walter A. Gilbert on July 3, 1996 and is headquartered in Boston, MA. | - |
R. Wayne Frost | M | 69 | - | |
Claire J. Lockey | F | 71 | 7 Jahre | |
Grace U. Shin | F | 59 | 9 Jahre | |
Richard A. Farley | M | - | 6 Jahre | |
Sarah O'Dowd | F | 74 | 1 Jahre | |
Mark Eisner | M | 58 | 3 Jahre |
Statistik
Land | Beziehungen | % des Gesamten |
---|---|---|
Vereinigte Staaten | 54 | 71,05% |
Finnland | 23 | 30,26% |
Alter der Beziehungen
Aktive
Vergangene
Herr
Frau
Aufsichtsräte
Führungskräfte
Ursprung der Beziehungen
- Börse
- Insiders
- Kalevi Kurkijärvi
- Persönliches Netzwerk